文献速递头颈与中枢神经肿瘤

贝伐珠单抗联合大分割放疗对比单纯放疗治疗老年胶质母细胞瘤:随机开放标签II期ARTE试验

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.
PubMed 文献 · Ann Oncol · 2018-01-01

ARTE是一项2:1随机、多中心、开放标签、非比较性II期试验,纳入≥65岁新诊断胶质母细胞瘤患者,比较大分割放疗(40 Gy/15次)联合贝伐珠单抗(10 mg/kg每14天)与单纯放疗。主要目的为观察贝伐珠单抗能否延长中位OS。结果显示联合组PFS延长(7.6 vs 4.8个月,P=0.003),但OS无差异(12.1 vs 12.2个月,P=0.77)。探索性分析提示RTK I甲基化亚型和proneural基因表达患者可能从贝伐珠单抗联合治疗中 preferential 获益。

要点

  • 贝伐珠单抗联合大分割放疗延长PFS但不延长OS。
  • 临床恶化延迟且更多患者停用激素。
  • RTK I甲基化亚型和proneural表达者PFS获益更明显。

核心结论

  • 在老年胶质母细胞瘤患者中,贝伐珠单抗联合放疗总体上未延长OS,不支持下述假设:贝伐珠单抗联合放疗普遍延长生存。
  • 分子生物标志物可能识别从贝伐珠单抗 preferential 获益的患者。

研究设计与样本

  • ARTE为2:1随机、多中心、开放标签、非比较性II期试验。
  • 纳入新诊断胶质母细胞瘤且年龄≥65岁患者,A组(N=50)接受大分割放疗(40 Gy/15次)联合贝伐珠单抗(10 mg/kg每14天),B组(N=25)接受单纯大分割放疗。
  • 主要目标为获得贝伐珠单抗联合放疗延长中位OS的证据;疗效按RANO标准评估,QoL采用EORTC QLQ-C30/BN20模块监测。
  • 探索性研究包括450k全甲基化组分子分型和基因表达分析。

主要发现

  • A组中位PFS长于B组(7.6个月 vs 4.8个月,P=0.003),但OS相似(12.1个月 vs 12.2个月,P=0.77)。
  • A组临床恶化延迟,更多患者停用激素。
  • A组PFS延长仅限于RTK I甲基化亚型肿瘤(HR 0.25,P=0.014)和proneural基因表达肿瘤(HR 0.29,P=0.025)。
  • 控制已知预后因素的OS Cox模型中,年龄<70岁(HR 0.52,P=0.018)和KPS 90%-100%(HR 0.51,P=0.026)与更优结局相关。
  • 将分子亚型纳入该模型后,RTK II基因甲基化亚型与更差OS相关(HR 1.73,P=0.076)。

关键数值与推荐

  • 中位PFS:A组7.6个月 vs B组4.8个月,P=0.003。
  • 中位OS:A组12.1个月 vs B组12.2个月,P=0.77。
  • RTK I甲基化亚型PFS的HR 0.25,P=0.014;proneural基因表达PFS的HR 0.29,P=0.025。
  • 年龄<70岁OS的HR 0.52,P=0.018;KPS 90%-100% OS的HR 0.51,P=0.026。
  • RTK II基因甲基化亚型OS的HR 1.73,P=0.076。

临床怎么用

  • 对于老年新诊断胶质母细胞瘤患者,不推荐常规在放疗基础上联合贝伐珠单抗以延长生存。
  • 贝伐珠单抗联合放疗可考虑用于改善PFS和延迟临床恶化,尤其在RTK I甲基化亚型或proneural表达肿瘤中。
  • 治疗决策时可结合年龄(<70岁)和KPS(90%-100%)等预后因素综合评估。

局限性

  • II期非比较性设计,样本量较小(A组50例,B组25例)。
  • 探索性分子分析结果需进一步验证。
  • 开放标签设计可能影响部分终点评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The addition of bevacizumab to temozolomide-based chemoradiotherapy (TMZ/RT → TMZ) did not prolong overall survival (OS) in patients with newly diagnosed glioblastoma in phase III trials. Elderly and frail patients are underrepresented in clinical trials, but early reports suggested preferential benefit in this population. PATIENTS AND METHODS: ARTE was a 2 : 1 randomized, multi-center, open-label, non-comparative phase II trial of hypofractionated RT (40 Gy in 15 fractions) with bevacizumab (10 mg/kg×14 days) (arm A, N = 50) or without bevacizumab (arm B, N = 25) in patients with newly diagnosed glioblastoma aged ≥65 years. The primary objective was to obtain evidence for prolongation of median OS by the addition of bevacizumab to RT. Response was assessed by RANO criteria. Quality of life (QoL) was monitored by the EORTC QLQ-C30/BN20 modules. Exploratory studies included molecular subtyping by 450k whole methylome and gene expression analyses. RESULTS: Median PFS was longer in arm A than in arm B (7.6 and 4.8 months, P = 0.003), but OS was similar (12.1 and 12.2 months, P = 0.77). Clinical deterioration was delayed and more patients came off steroids in arm A. Prolonged PFS in arm A was confined to tumors with the receptor tyrosine kinase (RTK) I methylation subtype (HR 0.25, P = 0.014) and proneural gene expression (HR 0.29, P = 0.025). In a Cox model of OS controlling for established prognostic factors, associations with more favorable outcome were identified for age <70 years (HR 0.52, P = 0.018) and Karnofsky performance score 90%-100% (HR 0.51, P = 0.026). Including molecular subtypes into that model identified an association of the RTK II gene methylation subtype with inferior OS (HR 1.73, P = 0.076). CONCLUSION: Efficacy outcomes and exploratory analyses of ARTE do not support the hypothesis that the addition of bevacizumab to RT generally prolongs survival in elderly glioblastoma patients. Molecular biomarkers may identify patients with preferential benefit from bevacizumab. CLINICAL TRIAL REGISTRATION NUMBER: NCT01443676.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Wirsching HG, Tabatabai G, Roelcke U, et al. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. Ann Oncol. 2018. PMID: 29648580. doi:10.1093/annonc/mdy120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。